Pdi Inc Com (NASDAQ:IDXG)

CAPS Rating: 1 out of 5

A sales and marketing services company, which serves the biopharmaceutical and life sciences industries.

Caps

How do you think IDXG will perform against the market?

Add Stock to CAPS Watchlist

All Players

25 Outperform
23 Underperform
 

All-Star Players

3 Outperform
18 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top IDXG Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

no1spec1al (< 20)
Submitted April 23, 2007

Trading below book value, new management. Their price was beaten down for loss of a large contract, but they've since picked up another. Not profitable at the moment, but with the company trading below book value your risks are pretty low. With the… More

NuvoRiche (79.29)
Submitted April 17, 2007

Provides outsourced sales & marketing force capability for Pharma companies, that can either replace or augment an in-house sales force. Currently beaten down by the loss of 3 major accounts as of Dec 06 (GSK, SNY, Astra-Zeneca) accounting for $126M… More

IDXG VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about IDXG.

Recs

0
Member Avatar skc0001 (< 20) Submitted: 5/14/2007 9:01:20 AM : Outperform Start Price: $100.30 IDXG Score: -192.24

A Value Proposition

Recs

1
Member Avatar no1spec1al (< 20) Submitted: 4/22/2007 9:10:39 PM : Outperform Start Price: $94.00 IDXG Score: -195.39

Trading below book value, new management. Their price was beaten down for loss of a large contract, but they've since picked up another. Not profitable at the moment, but with the company trading below book value your risks are pretty low. With the new sales director this stock can only get better.

Recs

1
Member Avatar NuvoRiche (79.29) Submitted: 4/17/2007 3:20:14 PM : Underperform Start Price: $95.00 IDXG Score: +197.19

Provides outsourced sales & marketing force capability for Pharma companies, that can either replace or augment an in-house sales force. Currently beaten down by the loss of 3 major accounts as of Dec 06 (GSK, SNY, Astra-Zeneca) accounting for $126M (56%) of revenues. Forward EPS -1.46 for '07 and negative again for '08. President of Sales just "resigned" in 4/07, and a somewhat nebulous "long-term strategic plan" will be implemented in 2007. Major selling point on this stock is that as of 4/07 it's trading below book value (P/B 0.88) giving potentially a margin of safety. But who knows, turnarounds can work. So I'll give it a short-term thumbs down, but may offer a good value opportunity for a risk-tolerant LT buy-and-hold portfolio.

Leaderboard

Find the members with the highest scoring picks in IDXG.

Score Leader

drakitin

drakitin (99.06) Score: +221.92

The Score Leader is the player with the highest score across all their picks in IDXG.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
drakitin 99.06 8/19/2008 Underperform 3Y $76.10 -98.21% +123.71% +221.92 0 Comment
chicagobears 89.97 3/13/2008 Underperform 5Y $85.00 -98.40% +122.25% +220.65 0 Comment
TMFNosediveflip 95.74 9/27/2006 Underperform 1Y $110.40 -98.77% +119.78% +218.55 0 Comment
rgonzo310 84.61 3/19/2008 Underperform 1Y $82.20 -98.35% +118.61% +216.96 0 Comment
BenBernanke 65.83 12/15/2006 Underperform 3M $105.30 -98.71% +105.17% +203.88 0 Comment
NuvoRiche 79.29 4/17/2007 Underperform 1Y $95.00 -98.57% +98.62% +197.19 1 Comment
UFShowboat < 20 4/23/2007 Underperform NS $94.00 -98.55% +96.84% +195.39 0 Comment
JoeySolitro3 98.33 12/19/2016 Underperform 5Y $9.30 -85.38% +22.35% +107.72 0 Comment
FriarPio 99.77 3/22/2017 Underperform 5Y $2.84 -52.11% +18.21% +70.32 0 Comment
RayNobleEsq 99.98 6/2/2017 Underperform 5Y $1.91 -28.80% +13.49% +42.28 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for IDXG.

Advertisement